ReviewVascular health and risk management2008
Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease.
Review in Vascular health and risk management, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Impact of Isomaltulose on Glycemic Response in Diabetic and Healthy Populations: A Meta-Analysis.Nutrients · 2025Pooled it
- Comparison between sodium-glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta-analysis.Journal of diabetes investigation · 2018Pooled it
- Expectations about and experiences with insulin therapy contribute to diabetes treatment satisfaction in insulin-naïve patients with type 2 diabetes.International journal of clinical practice · 2010Trial
- Activity prediction, structure-based drug design, molecular docking, and pharmacokinetic studies of 1,4-dihydropyridines derivatives as α-amylase inhibitors.Journal of Taibah University Medical Sciences · 2024Article
- Insulin therapy among diabetic patients in rural communities of Sub-Saharan Africa: a perspective review.Therapeutic advances in endocrinology and metabolism · 2024Review
- Design, synthesis, and evaluation of benzofuran-based chromenochalcones for antihyperglycemic and antidyslipidemic activities.RSC medicinal chemistry · 2023Article
- Synbiotics and Gut Microbiota: New Perspectives in the Treatment of Type 2 Diabetes Mellitus.Foods (Basel, Switzerland) · 2022Review
- Decisional Balance for Insulin Injection: Scale Development and Psychometric Testing.The journal of nursing research : JNR · 2019Article
- Evaluation of serum ferritin and some metal elements in type 2 diabetes mellitus patients: comparative cross-sectional study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2016Article
- Hypoglycemic agents and potential anti-inflammatory activity.Journal of inflammation research · 2016Review
- Treat-to-target trials in diabetes.Indian journal of endocrinology and metabolism · 2014 · on this mapReview
- Evaluation of antidiabetic prescriptions, cost and adherence to treatment guidelines: A prospective, cross-sectional study at a tertiary care teaching hospital.Journal of basic and clinical pharmacy · 2013Article
- Clinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATE.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2012Article
- Predictor variables and an equation for estimating HbA1c attainable by initiation of basal supported oral therapy.Journal of diabetes investigation · 2012Article
- Links between the Prophet Muhammad (PBUH) recommended foods and disease management: A review in the light of modern superfoods.International journal of health sciencesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with type 2 diabetes mellitus (T2DM) have an increased risk of cardiovascular disease (CVD). Unfortunately, several potential barriers exist for CVD risk management in diabetes, including the need for significant lifestyle changes, potential problems with hypoglycemia, weight gain, injection tolerability, treatment complexity with current diabetes therapies and other, unmodifiable factors. Improving glycemic control may impact CVD risk. Treatment of T2DM usually starts with lifestyle changes such as diet and exercise. When these become insufficient, pharmacotherapy is required. Various oral antidiabetic drugs (OADs) are available that reduce hyperglycemia. The first line of therapy is usually metformin, since it does not increase weight and seems to have a beneficial effect on CVD mortality and risk factors. As T2DM progresses, insulin treatment becomes necessary for the majority of patients. The last few years have seen the development of long-acting, rapid-acting, and premixed insulin analog formulations. The treat-to-target algorithms of recent studies combining OADs plus insulin analogs have demonstrated that patients can reach glycemic treatment targets with low risk of hypoglycemia, greater convenience, and--with some analogs--limited weight gain vs conventional insulins. These factors may possibly have a positive influence on CVD risk. Future studies will hopefully elucidate the benefits of this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.